All Pharma News
Yuhan makes $325M cancer bet to challenge Boehringer, Takeda

Yuhan makes $325M cancer bet to challenge Boehringer, Takeda
Nick Paul Taylor FIERCE BIOTECH
31 May 2023
Share Share
Hanmi, LG Chem, Yuhan race to develop new obesity drug

Hanmi, LG Chem, Yuhan race to develop new obesity drug
Kim Chan-hyuk KOREABIOMED
23 May 2022
Share Share
Yuhan gets $9.97M milestone payment from Boehringer Ingelheim for NASH therapy

Yuhan gets $9.97M milestone payment from Boehringer Ingelheim for NASH therapy
Shim Hyun-tai KOREABIOMED
17 Nov 2021
Share Share
Yuhan gets $65m from Janssen for lazertinib milestone achievement

Yuhan gets $65m from Janssen for lazertinib milestone achievement
KOREAHERALD
23 Nov 2020
Share Share
Yuhan in-licenses GI Innovation’s allergy treatment pipeline for $1.2b

Yuhan in-licenses GI Innovation’s allergy treatment pipeline for $1.2b
By Lim Jeong-yeo KOREAHERALD
01 Jul 2020
Share Share
After inking a string of pipeline deals, Boehringer Ingelheim is doing makeover

After inking a string of pipeline deals, Boehringer Ingelheim is doing makeover
John Carroll ENDPTS
26 Aug 2019
Share Share
Boehringer Ingelheim Gambles $2.62 Billion on Two Fibrotic Disease Deals

Boehringer Ingelheim Gambles $2.62 Billion on Two Fibrotic Disease Deals
Mark Terry BIOSPACE
19 Jul 2019
Share Share
Boehringer Ingelheim and Yuhan Corp. in US$870m NASH deal

Boehringer Ingelheim and Yuhan Corp. in US$870m NASH deal
EUROPEAN BIOTECHNOLOGY
02 Jul 2019
Share Share
Pfizer plant closures; Gilead-Yuhan NASH pact; Fujifilm expansions

Pfizer plant closures; Gilead-Yuhan NASH pact; Fujifilm expansions
Angus Liu FIERCE PHARMA
11 Jan 2019
Share Share
Glenmark in second licensing deal for anti-histamine

Glenmark in second licensing deal for anti-histamine
PRESS RELEASE
10 Jan 2019
Share Share